Multiple SclerosisPhase 1NCT07597668
A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations
A Phase 1 study testing RPH-035 and Ocrevus® in people with Multiple Sclerosis, run by R-Pharm at 23 sites in Russia.
Trial summary
The study goal is to establish the equivalence of pharmacokinetic (PK) properties, as well as the comparability of safety, immunogenicity (IG) and pharmacodynamics (PD) of the drug product RPH-035 (R-Pharm JSC, Russia) in comparison with the drug product Ocrevus® (F. Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- Multiple Sclerosis
- What is being tested?
- RPH-035 and Ocrevus®
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 180 participants
- Where
- 23 sitesRussia
- Study dates
- 16 Apr 2025to 24 Nov 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Patients shall meet all of the following inclusion criteria:
- Availability of the voluntarily signed and dated patient Informed Consent (IC) form for participation in this study
- Multiple sclerosis with exacerbations (relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS) with exacerbations) according to the McDonald diagnostic criteria as revised in 2017, with symptoms lasting at least 1 year before signing the IC form
- The patient's medical history includes the use of ≤ 3 prior multiple sclerosis disease modifying drugs (DMT)
- The patient has one of the following signs of disease activity:
- ≥ 2 documented disease exacerbations in the previous 24 months before the IC signing date
- ≥ 1 documented disease exacerbation in the previous 12 months before the IC signing date
- 1 documented exacerbation in the previous 24 months before the IC signing date and ≥ 1 documented brain lesion on the contrast-enhanced Magnetic Resonance Imaging (MRI) scan in the previous 6 months before the IC signing date
- Expanded Disability Status Scale (EDSS) index is 0-5.5 points inclusively on screening
- No Multiple sclerosis (MS) exacerbations within 30 days before the IC signing date and throughout the entire screening examination
- Ability, in the Investigator's opinion, to comply with the Protocol procedures and requirements
- Negative pregnancy test for female participants with preserved reproductive potential
- Consent of the patient with preserved reproductive potential to abstain from heterosexual contacts or to use reliable contraceptive methods, starting from the moment of the IC form signing, throughout the entire treatment period within the study, as well as for 12 months after the last ocrelizumab administration. Female participants are considered infertile if definitive amenorrhea was determined (from patient's words) retrospectively after 12 months of natural amenorrhea, i.e amenorrhea with an appropriate clinical status, such as a suitable age (between 45 and 55 years )
Patients cannot be included in the study if they meet at least one of the following exclusion criteria:
- Medical history of hypersensitivity to monoclonal antibody drugs or to any component of the investigational medicinal products
- Prior therapy with ocrelizumab
- Primary progressive multiple sclerosis or SPMS without exacerbations
- Contraindications for MRI, including intolerance to Gd-containing contrast agents and claustrophobia
- Medical history of other neurological diseases (excluding migraines) or first diagnosed on screening, including but not limited to the following:
- ischemic cerebrovascular disorders (e.g., stroke, transient ischemic attack) or spinal cord ischemia
- malignant and benign central nervous system (CNS) tumours (meningiomas, gliomas, etc.) requiring surgical intervention
- potential metabolic causes of myelopathy, identified from the medical history or in patient words (untreated vitamin B12 deficiency, etc.)
- infectious myelopathy (syphilis, Lyme disease, human T-lymphotropic virus 1 [HTLV-1], herpes zoster)
- hereditary progressive CNS degenerative disorder, MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, stroke)
- neuromyelitis optical spectrum disorders
- progressive multifocal leukoencephalopathy
- Systemic autoimmune disease (lupus, rheumatoid arthritis, antiphospholipid antibody syndrome, Sjorgen's syndrome, Behcet's syndrome)
- Sarcoidosis
- Medical history of severe, clinically significant brain or spinal cord injury (brain contusion, spinal cord compression)
- Medical history of the patient includes the following therapy:
- targeted biological B-cell therapy (ocrelizumab, rituximab or ofatumumab, etc.)
- bone marrow transplantation, lymphocyte irradiation
- any unregistered biological drug product for MS treatment
- The patient received any of the following therapies (subject to the time/dose restrictions specified):
- natalizumab (inclusion of such patients in the study is allowed, provided that the therapy was completed > 12 months before the IC signing date)
- fampridine (administration is allowed, provided only that the patient has been receiving continuous therapy with the drug product for at least 3 months before the IC signing date)
- alemtuzumab (< 4 years before the IC signing date)
- fingolimod (< 6 weeks before the IC signing date)
- dimethyl fumarate, siponimod (< 4 before the IC signing date)
- teriflunomide (< 3.5 months before the IC signing date), in case of accelerated elimination procedure < 2 weeks before the IC signing date)
- immunosuppressive drug products: azathioprine, mycophenolate mofetil, methotrexate, TNF-α inhibitors (< 6 months before the IC signing date) cyclophosphamide, mitoxantrone, cladribine (< 24 months before the IC signing date)
- interferon beta/glatiramer acetate (< 2 weeks before the IC signing date)
- immunoglobulin intravenous administration within < 12 weeks before the IC signing date
- plasmapheresis or plasma adsorption (< 21 days before the randomisation date)
- therapy with systemic glucocorticosteroids (GCS), adrenocorticotropic hormones (ACTH) < 1 month before MRI screening
- live or live attenuated vaccine within < 3 months before the IC signing date or vaccination plans for the study period
- Concomitant diseases that increase the patient's risk of AE development during the use of the investigational therapy or may affect the assessment of MS symptoms severity; mask, intensify, modify MS symptoms or cause clinical and laboratory-instrumental symptoms similar to those in MS as confirmed by primary documentation data:
- uncontrolled arterial hypertension characterised by systolic blood pressure (BP) above 150 mmHg or diastolic BP above 90 mmHg during the antihypertensive therapy
- medical history of moderate or severe heart failure (functional class III/IV according to the New York Heart Association (NYHA) classification), stable effort angina of functional class III-IV, unstable effort angina, or medical history of myocardial infarction less than 6 months before randomisation
- diagnosis of any clinically significant (in the opinion of the investigator) respiratory disease including, but not limited to, chronic obstructive pulmonary disease of grade 3 or 4 severity
- diagnosis of active liver disease or liver failure based on medical history
- Haematological disorders:
- haemoglobin < 80 g/L
- white blood cells (WBC) < 3.0 × 10^9/L
- absolute neutrophil count < 1.5 × 10^9/L
- absolute lymphocyte count < 0.5 × 10^9/L
- platelets < 100 × 10^9/L
- Renal impairment:
- creatinine > 1.5 × upper limit of normal (ULN) or glomerular filtration rate < 45 mL/min, calculated using CKD-EPI formula
- Hepatic impairment:
- bilirubin, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≥ 2 × ULN
- Presence of oncological pathology that is progressing or requires anti-tumour therapy (including hormonal therapy) within 5 years before the IC signing date, except for radically resected cervical carcinoma in situ or radically resected basal cell/squamous-cell carcinoma of skin
- Medical history of diverticulitis or other gastrointestinal tract (GI) disorders (e.g., inflammatory bowel disease, mechanical ileus, hernia) that can cause gastrointestinal (GI) perforations in patients
- Diseases (e.g., asthma, psoriasis) that require treatment with immunosuppressive biological drugs or systemic corticosteroids during the study
- medical history of primary and/or secondary immunodeficiencies (most commonly manifested by recurrent severe infections that are refractory to the standard treatment, in typical cases, these include upper and lower respiratory tract infections (e.g., sinusitis, bronchitis, pneumonia) and gastroenteritis, as well as severe bacterial infections (e.g., meningitis, sepsis))
- any other acute or chronic diseases in the medical history that may affect the interpretation of the study results or pose an unacceptable risk to the patient when using the investigational therapy (in the Investigator's opinion)
- One or more signs of depressed immune system function in the patient:
- serum IgG concentration < 4.0 g/L
- absolute CD4 + lymphocyte count < 0.25 × 10^9/L
- Absence of IgG antibodies to Varicella zoster or a positive PCR reaction to herpes viruses of types 4, 5, 6
- Positive result for any of the following tests: hepatitis B surface antigen (HBs Ag), hepatitis C virus antibodies (anti-HCV), human immunodeficiency virus antibodies 1 and 2 (anti-HIV1 and anti-HIV2 Ab), or a blood test for syphilis on screening
- Presence of the following infections in a patient:
- infections that caused an increased body temperature above normal range or required the use of oral antibacterial and/or antiviral drugs within 4 weeks before randomisation, hospitalisation, or the use of parenteral anti-infective drugs within 2 months before randomisation (the exception is detection of asymptomatic herpes virus types 4, 5 and/or 6 on screening and their treatment within screening according to the study site's standards)
- confirmed SARS-CoV-2 coronavirus infection within 1 month before randomisation
- medical history of severe, recurrent, or chronic infections (including severe herpes infection, herpes zoster, sepsis, abscess, invasive fungal infections) in which, in the Investigator's opinion, the investigational medicinal product may cause harm to the patient
- medical history of active or latent tuberculosis, signs of tuberculosis infection based on the TB-feron test or Quantiferon test results and the chest X-ray performed during screening (it is possible to use the chest X-ray results performed no more than 2 months before the IC signing date)
- Inability to administer the investigational medicinal product intravenously and to collect venous blood
- Intolerance to oral or intravenous corticosteroids
- Pregnancy, breastfeeding, and planning pregnancy during the period of participation in the study
- Major surgeries (i.e., those involving opening of the abdominal cavity, chest cavity, skull) less than 60 days before the IC signing date (it is acceptable to include patients who have been fully recovered according to the Investigator's assessment), or the patient is scheduled to undergo major surgery during the period of participation in the study
- Conditions that limit the patient's ability to comply with the protocol requirements, in the Investigator's opinion (e.g., medical history of dementia or mental disorders (including depression, schizophrenia), as well as information about drug or alcohol addiction within 12 months before the IC signing date, etc.)
- Concurrent participation in other interventional clinical trials, participation in other clinical trials less than 30 days or less than 5 T1/2 of the investigational drugs before the IC signing date (provided the patient has received at least one administration of the investigational therapy), and previous participation in this clinical trial (provided the patient has received at least one administration of the investigational therapy)
Trial locations and contacts
23 sites in 1 country.
23 sites in 1 country
Russia23 sites
State Autonomous Healthcare Institution Regional Clinical Hospital No. 3
Chelyabinsk, 454021
Kazan State Medical Academy, branch of the Federal State Budgetary Educational Institution of Additional Professional Education Russian Medical Academy of Continuing Professional Education
Kazan', 420061
State Autonomous Healthcare Institution "Interregional Clinical and Diagnostic Center"
Kazan', 420101
Kirov Regional State Clinical Budgetary Healthcare Institution "Center for Cardiology and Neurology"
Kirov, 610007
Limited Liability Company DOCKBRAIN
Krasnodar, 350049
Federal State Budgetary Institution Federal Siberian Scientific and Clinical Center of the Federal Medical and Biological Agency
Krasnoyarsk, 660037
Federal State Budgetary Scientific Institution "Russian Center for Neurology and Neurosciences"
Moscow, 125367
State Budgetary Healthcare Institution of the City of Moscow "City Clinical Hospital No. 24 of the Moscow Health Department"
Moscow, 127015
Research Lab LLC
Moscow, 127521
State Budgetary Healthcare Institution of the Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital named after N. A. Semashko"
Nizhny Novgorod, 603126
MEDIS Limited Liability Company
Nizhny Novgorod, 603137
Federal State Budgetary Healthcare Institution "Siberian District Medical Center of the Federal Medical and Biological Agency"
Novosibirsk, 630007
State Budgetary Healthcare Institution of the Novosibirsk Region "State Novosibirsk Regional Clinical Hospital"
Novosibirsk, 630087
State Budgetary Healthcare Institution of the Perm Region "Perm Regional Clinical Hospital of the Order of the Badge of Honor"
Perm, 614045
Rostov Regional Clinical Hospital, State Budgetary Institution of the Rostov Region
Rostov-on-Don, 344015
LLC "Center for Diagnostics and Rehabilitation "PRAKSIMED"
Saint Petersburg, 194223
State Budgetary Healthcare Institution Leningrad Regional Clinical Hospital
Saint Petersburg, 194291
St. Petersburg State Budgetary Healthcare Institution "City Clinical Hospital No. 31"
Saint Petersburg, 197110
State Budgetary Healthcare Institution of the Republic of Mordovia "Republican Clinical Hospital No. 4"
Saransk, 430032
Smolensk Regional Clinical Hospital, Regional State Budgetary Healthcare Institution
Smolensk, 214018
Federal State Budgetary Educational Institution of Higher Education "Siberian State Medical University" of the Ministry of Health of the Russian Federation
Tomsk, 634050
Joint Stock Company "Medical and Sanitary Unit "Neftyanik"
Tyumen, 625048
Ulyanovsk Regional Clinical Hospital, a public health institution
Ulyanovsk, 432017
About this study
Official title: A Multicentre, Double-blind, Randomised, Comparative Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity Study of RPH-035 Versus Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations
The study goal is to establish the equivalence of pharmacokinetic (PK) properties, as well as the comparability of safety, immunogenicity (IG) and pharmacodynamics (PD) of the drug product RPH-035 (R-Pharm JSC, Russia) in comparison with the drug product Ocrevus® (F. Hoffmann-La Roche Ltd., Switzerland) when used in patients with multiple sclerosis (MS)
Read the detailed description
This study is a multicentre, double-blind, randomised, comparative Phase I study
The clinical study includes the following periods:
- Screening period: days [-27…-0] (up to 1st administration of study therapy)
- Main period: weeks [1-49] Patients who meet the eligibility criteria shall be randomised in a 1: 1 ratio to one of two study arms: RPH-035 and Ocrevus® During the Main Period, the patients will receive their first infusion of ocrelizumab (RPH-035 or Ocrevus®) at a dose of 300 mg, followed by another 300 mg of the drug product after 2 weeks. The duration of ocrelizumab administration will be 2.5 hours ± 15 minutes. The third infusion at a dose of 600 mg should be administered 6 months after the first infusion of the initial dose. The administration is scheduled for the "Week 25" visit. The Main Period includes regular collection of data on complaints and symptoms, physical examination, assessment of vital signs (measurement of body temperature, blood pressure (BP), pulse), body weight measurement, monitoring of laboratory parameters (clinical and biochemical blood tests, measurement of the concentration of immunoglobulin type G (IgG), general urine analysis), IG analysis, electrocardiogram (ECG), magnetic resonance imaging (MRI) at weeks 9, 17, 25, 49, neurological examination, assessment according to the Expanded Disability Status Scale (EDSS), registration of adverse events/serious adverse events (AEs/SAEs). MRI and assessment of response to therapy within the Main Period will be performed approximately once every 8 weeks during the first six months of the study (week 1 - week 25), then at week 49 The week 49 visit consists of two stages: prior to drug administration, procedures are performed to assess the safety and effectiveness of the blinded therapy. After receiving and analysing the results, the research physician decides whether to terminate or extend therapy. If therapy needs to be continued, the patient is transferred to the follow-up period
- After-Therapy period: weeks [49-97] During the After-Therapy Period, beginning at week 49, all patients will receive RPH-035 therapy, including those who received Ocrevus® therapy during the Main Period. Visits are also included in this period, which are conducted in the form of telephone contacts to assess the patient's well-being, collect data on concomitant therapy and possible AEs During the After-Therapy Period, patients will receive an IV infusion of ocrelizumab (RPH-035) at a dose of 600 mg at "Week 49", "Week 73", and "Week 97" visits
- Follow-up period (FU)
The first follow-up visit (FU) is performed 28 ± 3 days after the last visit (scheduled or unscheduled)
- For patients who have completed their participation in the Main Period as planned and are not included in the After-Therapy Period, the FU visit will be conducted once 28 ± 3 days after day 337
- For patients who completed therapy early before day 337 in the study due to treatment failure, the first FU visit will be conducted 28 ± 3 days after the last visit conducted within the therapy (scheduled or unscheduled), but within 337 days. Further FU visits will be conducted in the form of telephone contacts with the patient/patient's relatives with a frequency of 1 time per 8 weeks (±7 days) until day 337 during the study or informed consent (IC) recall (whichever occurs first)
- If a patient completes therapy in the study early before day 337 of the study for a reason not related to treatment failure and is not prescribed another treatment regimen, FU visits will be conducted in the form of an assessment of the response to therapy with MRI once every 8 weeks ± 3 days (from the date of the first FU visit) until day 337 of the study or until another therapy is prescribed/IC is recalled (whichever occurs first). If another treatment regimen is prescribed, FU visits for these patients will continue at a frequency of once every 8 weeks (±7 days) until day 337 within the study or IC recall (whichever occurs first) in the form of telephone contacts with the patient/patient's relatives
- For patients who completed therapy during the after-therapy period either planned or early for any reason, 1 FU visit is scheduled 28 ± 3 days after the last visit during the after-therapy period. After this visit, the patient is considered to have completed the study
- Conditions
- Multiple Sclerosis
- Being tested
- RPH-035, Ocrevus®
- Keywords
- RPH-035, Ocrelizumab, Multiple Sclerosis
- Medical subject headings
- Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RPH-035Drug
Also called ocrelizumab, L04785
300 mg/10 mL (30 mg/mL) concentrate for solution for infusions in a single-dose vial
For the 1st and 2nd infusions, 300 mg (10 mL) of ocrelizumab is diluted in 0.9% sodium chloride to a final concentration of approximately 1.2 mg/mL. For the 3rd infusion, 600 mg (20 mL) of ocrelizumab is diluted in 0.9% sodium chloride to a final concentration of approximately 1.2 mg/mL
Ocrevus®Drug
Also called ocrelizumab
300 mg/10 mL (30 mg/mL) concentrate for solution for infusions in a single-dose vial
For the 1st and 2nd infusions, 300 mg (10 mL) of ocrelizumab is diluted in 0.9% sodium chloride to a final concentration of approximately 1.2 mg/mL. For the 3rd infusion, 600 mg (20 mL) of ocrelizumab is diluted in 0.9% sodium chloride to a final concentration of approximately 1.2 mg/mL
| Study group | Role | What they receive |
|---|---|---|
| RPH-035 | Experimental | During the Main Period, the patients receive their first infusion of ocrelizumab (RPH-035) at a dose of 300 mg, followed by another 300 mg of the drug product after 2 weeks. The duration of ocrelizumab administration is 2.5 hours ± 15 minutes. The third infusion at a dose of 600 mg is administered 6 months after the first infusion of the initial dose
During the After-Therapy Period, patients will receive an IV infusion of 600 mg of ocrelizumab (RPH-035) at weeks 49, 73, and 97
Premedication is mandatory and is carried out according to the following scheme:
* methylprednisolone at a dose of 100 mg (or dexamethasone at a dose of 18.8 mg, or an equivalent drug product) intravenously 30 ± 10 minutes before the start of each infusion
* antihistamine drug (e.g., diphenhydramine, suprastin, or an equivalent drug product) 30-60 minutes before the start of each infusion
* antipyretic drug (e.g., paracetamol) 30-60 minutes before the start of each infusion Receives: Drug: RPH-035 |
| Ocrevus® | Active comparator | During the Main Period, the patients receive their first infusion of ocrelizumab (Ocrevus®) at a dose of 300 mg, followed by another 300 mg of the drug product after 2 weeks. The duration of ocrelizumab administration is 2.5 hours ± 15 minutes. The third infusion at a dose of 600 mg is administered 6 months after the first infusion of the initial dose
Premedication is mandatory and is carried out according to the following scheme:
* methylprednisolone at a dose of 100 mg (or dexamethasone at a dose of 18.8 mg, or an equivalent drug product) intravenously 30 ± 10 minutes before the start of each infusion
* antihistamine drug (e.g., diphenhydramine, suprastin, or an equivalent drug product) 30-60 minutes before the start of each infusion
* antipyretic drug (e.g., paracetamol) 30-60 minutes before the start of each infusion Receives: Drug: Ocrevus® |
What is being measured
The primary outcome is the main question the study is designed to answer.
The area under the concentration-time pharmacokinetic curve (AUC (14-169 days)) of ocrelizumab
The area under the concentration-time pharmacokinetic curve of ocrelizumab after the second (single) administration, truncated at Day 169 (AUC (14-169 days))
Measured: Day 14 to Day 169
Secondary outcomes (14)
The area under the concentration-time pharmacokinetic curve (AUC (0-14 days)) of ocrelizumab
The area under the concentration-time pharmacokinetic curve of ocrelizumab after the first (single) IV administration, truncated at Day 14 (AUC (0-14 days))
Measured: Up to Day 14
Maximum serum concentration of ocrelizumab after the first administration (Cmax (0-14 days))
Maximum serum concentration of ocrelizumab after the first administration (Cmax (0-14 days))
Measured: Up to Day 14
Maximum serum concentration of ocrelizumab after the second administration (Cmax (14-169 days))
Maximum serum concentration of ocrelizumab after the second administration (Cmax (14-169 days))
Measured: Day 14 to Day 169
Percentage of patients with adverse reactions (ARs) of any severity
Adverse reactions (ARs) are all unfavourable and unintended reactions to the drug products associated with their administration in any dose, the causal relationship between their administration and adverse events (AEs) is at least possible, meaning that such a relationship cannot be excluded
Measured: Up to Day 337
Percentage of patients with adverse events (AEs) of any severity
An adverse event (AE) is any event observed in a clinical trial subject after the drug product administration, which is unfavourable from a medical point of view and may not have a causal relationship with its administration
Measured: Up to Day 337
Percentage of patients with AEs of severity grade ≥ 3
Percentage of patients with AEs of severity grade ≥ 3 per CTCAE 5.0
Measured: Up to Day 337
Percentage of patients with ARs of severity grade ≥ 3
Percentage of patients with ARs of severity grade ≥ 3 per CTCAE 5.0
Measured: Up to Day 337
Percentage of patients with serious adverse events (SAEs)
A serious adverse event (SAE) is any unfavourable medical event that, regardless of the drug product dose:
- leads to death
- poses a threat to life
- requires hospitalisation or its prolongation
- leads to persistent or severe disability/incapacitation
- is a congenital abnormality or developmental defect
- requires medical intervention to prevent the development of the conditions listed above
Measured: Up to Day 337
Percentage of patients with serious adverse reactions (SARs)
A serious adverse reaction (SAR) is an adverse reaction that is characterised by the criteria of seriousness:
- leads to death
- poses a threat to life
- requires hospitalisation or its prolongation
- leads to persistent or severe disability/incapacitation
- is a congenital abnormality or developmental defect
- requires medical intervention to prevent the development of the conditions listed above
Measured: Up to day 337
Percentage of patients who required discontinuation of therapy due to adverse events/adverse reactions (AEs/ARs)
Percentage of patients who required discontinuation of therapy due to AEs/ARs
Measured: Up to Day 337
Binding anti-drug antibodies (ADA) to ocrelizumab over a period of up to 24 weeks from the start of the therapy
Binding anti-drug antibodies (ADA) to ocrelizumab are assessed on Day 1 (pre-dose), 57, 113, 169 (pre-dose)
Measured: Up to Day 169
Binding anti-drug antibodies (ADA) to ocrelizumab over a period of up to 48 weeks from the start of the therapy
Binding anti-drug antibodies (ADA) to ocrelizumab are assessed on Day 1 (pre-dose), 57, 113, 169 (pre-dose), 225, 281, 337 (pre-dose)
Measured: Up to Day 337
Neutralizing antibodies (nAB) to ocrelizumab over a period of up to 24 weeks from the start of therapy
Neutralizing antibodies (nAB) to ocrelizumab are assessed on Day 1 (pre-dose), 57, 113, 169 (pre-dose)
Measured: Up to Day 169
Neutralizing antibodies (nAB) to ocrelizumab over a period of up to 48 weeks from the start of therapy
Neutralizing antibodies (nAB) to ocrelizumab are assessed on Day 1 (pre-dose), 57, 113, 169 (pre-dose), 225, 281, 337 (pre-dose)
Measured: Up to Day 337
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 May 2026
- Study start16 Apr 2025
- Primary completion2 Jun 2026
- Study completion24 Nov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 180 participants (estimated)
Sponsor and investigators
- Lead sponsor
- R-Pharm
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Mikhail Samsonov, Study director, R-Pharm
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07597668
- Sponsor's protocol ID
- CL04785171
- Status last verified
- Jul 2026
- First submitted
- 13 Apr 2026
- Last updated
- 14 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicentre, Double-blind, Randomised, Comparative Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity Study of RPH-035 Versus Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations
- ClinicalTrials.gov ID
- NCT07597668
- Acronym / sponsor ID
- CL04785171
- Conditions
- Multiple Sclerosis
- Keywords
- RPH-035, Ocrelizumab, Multiple Sclerosis
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 180 participants (estimated)
- Lead sponsor
- R-PharmIndustry (pharma, biotech, devices)
- Study start
- 16 Apr 2025 (actual)
- Primary completion
- 2 Jun 2026 (actual)
- Study completion
- 24 Nov 2027 (estimated)
- First posted
- 19 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study goal is to establish the equivalence of pharmacokinetic (PK) properties, as well as the comparability of safety, immunogenicity (IG) and pharmacodynamics (PD) of the drug product RPH-035 (R-Pharm JSC, Russia) in comparison with the drug product Ocrevus® (F. Hoffmann-La Roche Ltd., Switzerland) when used in patients with multiple sclerosis (MS)
Detailed description
This study is a multicentre, double-blind, randomised, comparative Phase I study
The clinical study includes the following periods:
- Screening period: days [-27…-0] (up to 1st administration of study therapy)
- Main period: weeks [1-49] Patients who meet the eligibility criteria shall be randomised in a 1: 1 ratio to one of two study arms: RPH-035 and Ocrevus® During the Main Period, the patients will receive their first infusion of ocrelizumab (RPH-035 or Ocrevus®) at a dose of 300 mg, followed by another 300 mg of the drug product after 2 weeks. The duration of ocrelizumab administration will be 2.5 hours ± 15 minutes. The third infusion at a dose of 600 mg should be administered 6 months after the first infusion of the initial dose. The administration is scheduled for the "Week 25" visit. The Main Period includes regular collection of data on complaints and symptoms, physical examination, assessment of vital signs (measurement of body temperature, blood pressure (BP), pulse), body weight measurement, monitoring of laboratory parameters (clinical and biochemical blood tests, measurement of the concentration of immunoglobulin type G (IgG), general urine analysis), IG analysis, electrocardiogram (ECG), magnetic resonance imaging (MRI) at weeks 9, 17, 25, 49, neurological examination, assessment according to the Expanded Disability Status Scale (EDSS), registration of adverse events/serious adverse events (AEs/SAEs). MRI and assessment of response to therapy within the Main Period will be performed approximately once every 8 weeks during the first six months of the study (week 1 - week 25), then at week 49 The week 49 visit consists of two stages: prior to drug administration, procedures are performed to assess the safety and effectiveness of the blinded therapy. After receiving and analysing the results, the research physician decides whether to terminate or extend therapy. If therapy needs to be continued, the patient is transferred to the follow-up period
- After-Therapy period: weeks [49-97] During the After-Therapy Period, beginning at week 49, all patients will receive RPH-035 therapy, including those who received Ocrevus® therapy during the Main Period. Visits are also included in this period, which are conducted in the form of telephone contacts to assess the patient's well-being, collect data on concomitant therapy and possible AEs During the After-Therapy Period, patients will receive an IV infusion of ocrelizumab (RPH-035) at a dose of 600 mg at "Week 49", "Week 73", and "Week 97" visits
- Follow-up period (FU)
The first follow-up visit (FU) is performed 28 ± 3 days after the last visit (scheduled or unscheduled)
- For patients who have completed their participation in the Main Period as planned and are not included in the After-Therapy Period, the FU visit will be conducted once 28 ± 3 days after day 337
- For patients who completed therapy early before day 337 in the study due to treatment failure, the first FU visit will be conducted 28 ± 3 days after the last visit conducted within the therapy (scheduled or unscheduled), but within 337 days. Further FU visits will be conducted in the form of telephone contacts with the patient/patient's relatives with a frequency of 1 time per 8 weeks (±7 days) until day 337 during the study or informed consent (IC) recall (whichever occurs first)
- If a patient completes therapy in the study early before day 337 of the study for a reason not related to treatment failure and is not prescribed another treatment regimen, FU visits will be conducted in the form of an assessment of the response to therapy with MRI once every 8 weeks ± 3 days (from the date of the first FU visit) until day 337 of the study or until another therapy is prescribed/IC is recalled (whichever occurs first). If another treatment regimen is prescribed, FU visits for these patients will continue at a frequency of once every 8 weeks (±7 days) until day 337 within the study or IC recall (whichever occurs first) in the form of telephone contacts with the patient/patient's relatives
- For patients who completed therapy during the after-therapy period either planned or early for any reason, 1 FU visit is scheduled 28 ± 3 days after the last visit during the after-therapy period. After this visit, the patient is considered to have completed the study
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| RPH-035 | Experimental | Drug: RPH-035During the Main Period, the patients receive their first infusion of ocrelizumab (RPH-035) at a dose of 300 mg, followed by another 300 mg of the drug product after 2 weeks. The duration of ocrelizumab administration is 2.5 hours ± 15 minutes. The third infusion at a dose of 600 mg is administered 6 months after the first infusion of the initial dose During the After-Therapy Period, patients will receive an IV infusion of 600 mg of ocrelizumab (RPH-035) at weeks 49, 73, and 97 Premedication is mandatory and is carried out according to the following scheme: * methylprednisolone at a dose of 100 mg (or dexamethasone at a dose of 18.8 mg, or an equivalent drug product) intravenously 30 ± 10 minutes before the start of each infusion * antihistamine drug (e.g., diphenhydramine, suprastin, or an equivalent drug product) 30-60 minutes before the start of each infusion * antipyretic drug (e.g., paracetamol) 30-60 minutes before the start of each infusion |
| Ocrevus® | Active comparator | Drug: Ocrevus®During the Main Period, the patients receive their first infusion of ocrelizumab (Ocrevus®) at a dose of 300 mg, followed by another 300 mg of the drug product after 2 weeks. The duration of ocrelizumab administration is 2.5 hours ± 15 minutes. The third infusion at a dose of 600 mg is administered 6 months after the first infusion of the initial dose Premedication is mandatory and is carried out according to the following scheme: * methylprednisolone at a dose of 100 mg (or dexamethasone at a dose of 18.8 mg, or an equivalent drug product) intravenously 30 ± 10 minutes before the start of each infusion * antihistamine drug (e.g., diphenhydramine, suprastin, or an equivalent drug product) 30-60 minutes before the start of each infusion * antipyretic drug (e.g., paracetamol) 30-60 minutes before the start of each infusion |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RPH-035Also: ocrelizumab, L04785300 mg/10 mL (30 mg/mL) concentrate for solution for infusions in a single-dose vial For the 1st and 2nd infusions, 300 mg (10 mL) of ocrelizumab is diluted in 0.9% sodium chloride to a final concentration of approximately 1.2 mg/mL. For the 3rd infusion, 600 mg (20 mL) of ocrelizumab is diluted in 0.9% sodium chloride to a final concentration of approximately 1.2 mg/mL | Drug | RPH-035 |
| Ocrevus®Also: ocrelizumab300 mg/10 mL (30 mg/mL) concentrate for solution for infusions in a single-dose vial For the 1st and 2nd infusions, 300 mg (10 mL) of ocrelizumab is diluted in 0.9% sodium chloride to a final concentration of approximately 1.2 mg/mL. For the 3rd infusion, 600 mg (20 mL) of ocrelizumab is diluted in 0.9% sodium chloride to a final concentration of approximately 1.2 mg/mL | Drug | Ocrevus® |
Primary outcome
The area under the concentration-time pharmacokinetic curve (AUC (14-169 days)) of ocrelizumab
Time frame: Day 14 to Day 169
The area under the concentration-time pharmacokinetic curve of ocrelizumab after the second (single) administration, truncated at Day 169 (AUC (14-169 days))
14 secondary outcomes
The area under the concentration-time pharmacokinetic curve (AUC (0-14 days)) of ocrelizumab
Time frame: Up to Day 14
Maximum serum concentration of ocrelizumab after the first administration (Cmax (0-14 days))
Time frame: Up to Day 14
Maximum serum concentration of ocrelizumab after the second administration (Cmax (14-169 days))
Time frame: Day 14 to Day 169
Percentage of patients with adverse reactions (ARs) of any severity
Time frame: Up to Day 337
Percentage of patients with adverse events (AEs) of any severity
Time frame: Up to Day 337
Percentage of patients with AEs of severity grade ≥ 3
Time frame: Up to Day 337
Percentage of patients with ARs of severity grade ≥ 3
Time frame: Up to Day 337
Percentage of patients with serious adverse events (SAEs)
Time frame: Up to Day 337
Percentage of patients with serious adverse reactions (SARs)
Time frame: Up to day 337
Percentage of patients who required discontinuation of therapy due to adverse events/adverse reactions (AEs/ARs)
Time frame: Up to Day 337
Binding anti-drug antibodies (ADA) to ocrelizumab over a period of up to 24 weeks from the start of the therapy
Time frame: Up to Day 169
Binding anti-drug antibodies (ADA) to ocrelizumab over a period of up to 48 weeks from the start of the therapy
Time frame: Up to Day 337
Neutralizing antibodies (nAB) to ocrelizumab over a period of up to 24 weeks from the start of therapy
Time frame: Up to Day 169
Neutralizing antibodies (nAB) to ocrelizumab over a period of up to 48 weeks from the start of therapy
Time frame: Up to Day 337
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2026.
Related trials for Multiple Sclerosis
RecruitingPhase 3
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Multiple Sclerosis
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingPhase 4
Individualised Cryoneurolysis to Treat Pain in the Context of Spasticity in the Upper and Lower Extremities
Centreal Neurological Condition, Acquired Brain Injury (Including Stroke)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mikhail Samsonov study director
R-Pharm
23 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing RPH-035 and Ocrevus® in people with Multiple Sclerosis, run by R-Pharm at 23 sites in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 14 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 23 sites in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The area under the concentration-time pharmacokinetic curve (AUC (14-169 days)) of ocrelizumab (time frame: Day 14 to Day 169). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2026; AzTrials last refreshed its copy on 7 Nov 2026.